The global Pharmaceutical CDMO market size was valued at US$ 125480 million in 2023. With growing demand in downstream market, the Pharmaceutical CDMO is forecast to a readjusted size of US$ 214600 million by 2030 with a CAGR of 8.0% during review period.
The research report highlights the growth potential of the global Pharmaceutical CDMO market. Pharmaceutical CDMO are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Pharmaceutical CDMO. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Pharmaceutical CDMO market.
A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.
Contract Pharmaceutical Manufacturing is part of CDMO, refers to accept commissioned from pharmaceutical companies, provide the service about API production, FDF production, packaging.
Pharmaceutical companies are likely to outsource a wide range of manufacturing related activities including 鈥� primary and secondary packaging, formulation, active ingredient manufacturing, labeling, clinical supplies, sterilization, manufacturing of chemical intermediates, etc. CDMOs support pharmaceutical companies at all stages of the process of making medicines: by providing services in the research and development stages, by offering support in manufacturing, and by providing formulating and finishing processes.
The key service providers of the Pharmaceutical CDMO in the world are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among which the market share of the top three service providers exceeds 10%, and Lonza is the largest service provider. The services provided by global pharmaceutical CDMO are mainly distributed in North America, Europe and China, among which the top three regions account for nearly 60% of the market share, and North America is currently the largest service provider. In terms of its service type, the growth rate of FDF CDMO is relatively fast. At present, the market share of API CDMO is the highest, more than 40%, followed by FDF CDMO, packaging CDMO and clinical CDMO. In terms of its application, pharmaceutical company are the largest application field, with a market share of more than 60%, followed by biotechnology company.
Key Features:
The report on Pharmaceutical CDMO market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Pharmaceutical CDMO market. It may include historical data, market segmentation by Type (e.g., API CDMO, FDF CDMO), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Pharmaceutical CDMO market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Pharmaceutical CDMO market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Pharmaceutical CDMO industry. This include advancements in Pharmaceutical CDMO technology, Pharmaceutical CDMO new entrants, Pharmaceutical CDMO new investment, and other innovations that are shaping the future of Pharmaceutical CDMO.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Pharmaceutical CDMO market. It includes factors influencing customer ' purchasing decisions, preferences for Pharmaceutical CDMO product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Pharmaceutical CDMO market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Pharmaceutical CDMO market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Pharmaceutical CDMO market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Pharmaceutical CDMO industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Pharmaceutical CDMO market.
麻豆原创 Segmentation:
Pharmaceutical CDMO market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO
Segmentation by application
Pharmaceutical Company
Biotechnology Company
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Pharmaceutical CDMO 麻豆原创 Size 2019-2030
2.1.2 Pharmaceutical CDMO 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Pharmaceutical CDMO Segment by Type
2.2.1 API CDMO
2.2.2 FDF CDMO
2.2.3 Packaging CDMO
2.2.4 Clinical CDMO
2.3 Pharmaceutical CDMO 麻豆原创 Size by Type
2.3.1 Pharmaceutical CDMO 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Pharmaceutical CDMO 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Pharmaceutical CDMO Segment by Application
2.4.1 Pharmaceutical Company
2.4.2 Biotechnology Company
2.4.3 Other
2.5 Pharmaceutical CDMO 麻豆原创 Size by Application
2.5.1 Pharmaceutical CDMO 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Pharmaceutical CDMO 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Pharmaceutical CDMO 麻豆原创 Size by Player
3.1 Pharmaceutical CDMO 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Pharmaceutical CDMO Revenue by Players (2019-2024)
3.1.2 Global Pharmaceutical CDMO Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Pharmaceutical CDMO Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Pharmaceutical CDMO by Regions
4.1 Pharmaceutical CDMO 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Pharmaceutical CDMO 麻豆原创 Size Growth (2019-2024)
4.3 APAC Pharmaceutical CDMO 麻豆原创 Size Growth (2019-2024)
4.4 Europe Pharmaceutical CDMO 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Pharmaceutical CDMO 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Pharmaceutical CDMO 麻豆原创 Size by Country (2019-2024)
5.2 Americas Pharmaceutical CDMO 麻豆原创 Size by Type (2019-2024)
5.3 Americas Pharmaceutical CDMO 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pharmaceutical CDMO 麻豆原创 Size by Region (2019-2024)
6.2 APAC Pharmaceutical CDMO 麻豆原创 Size by Type (2019-2024)
6.3 APAC Pharmaceutical CDMO 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Pharmaceutical CDMO by Country (2019-2024)
7.2 Europe Pharmaceutical CDMO 麻豆原创 Size by Type (2019-2024)
7.3 Europe Pharmaceutical CDMO 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Pharmaceutical CDMO by Region (2019-2024)
8.2 Middle East & Africa Pharmaceutical CDMO 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Pharmaceutical CDMO 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Pharmaceutical CDMO 麻豆原创 Forecast
10.1 Global Pharmaceutical CDMO Forecast by Regions (2025-2030)
10.1.1 Global Pharmaceutical CDMO Forecast by Regions (2025-2030)
10.1.2 Americas Pharmaceutical CDMO Forecast
10.1.3 APAC Pharmaceutical CDMO Forecast
10.1.4 Europe Pharmaceutical CDMO Forecast
10.1.5 Middle East & Africa Pharmaceutical CDMO Forecast
10.2 Americas Pharmaceutical CDMO Forecast by Country (2025-2030)
10.2.1 United States Pharmaceutical CDMO 麻豆原创 Forecast
10.2.2 Canada Pharmaceutical CDMO 麻豆原创 Forecast
10.2.3 Mexico Pharmaceutical CDMO 麻豆原创 Forecast
10.2.4 Brazil Pharmaceutical CDMO 麻豆原创 Forecast
10.3 APAC Pharmaceutical CDMO Forecast by Region (2025-2030)
10.3.1 China Pharmaceutical CDMO 麻豆原创 Forecast
10.3.2 Japan Pharmaceutical CDMO 麻豆原创 Forecast
10.3.3 Korea Pharmaceutical CDMO 麻豆原创 Forecast
10.3.4 Southeast Asia Pharmaceutical CDMO 麻豆原创 Forecast
10.3.5 India Pharmaceutical CDMO 麻豆原创 Forecast
10.3.6 Australia Pharmaceutical CDMO 麻豆原创 Forecast
10.4 Europe Pharmaceutical CDMO Forecast by Country (2025-2030)
10.4.1 Germany Pharmaceutical CDMO 麻豆原创 Forecast
10.4.2 France Pharmaceutical CDMO 麻豆原创 Forecast
10.4.3 UK Pharmaceutical CDMO 麻豆原创 Forecast
10.4.4 Italy Pharmaceutical CDMO 麻豆原创 Forecast
10.4.5 Russia Pharmaceutical CDMO 麻豆原创 Forecast
10.5 Middle East & Africa Pharmaceutical CDMO Forecast by Region (2025-2030)
10.5.1 Egypt Pharmaceutical CDMO 麻豆原创 Forecast
10.5.2 South Africa Pharmaceutical CDMO 麻豆原创 Forecast
10.5.3 Israel Pharmaceutical CDMO 麻豆原创 Forecast
10.5.4 Turkey Pharmaceutical CDMO 麻豆原创 Forecast
10.5.5 GCC Countries Pharmaceutical CDMO 麻豆原创 Forecast
10.6 Global Pharmaceutical CDMO Forecast by Type (2025-2030)
10.7 Global Pharmaceutical CDMO Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Lonza
11.1.1 Lonza Company Information
11.1.2 Lonza Pharmaceutical CDMO Product Offered
11.1.3 Lonza Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Lonza Main Business Overview
11.1.5 Lonza Latest Developments
11.2 Catalent
11.2.1 Catalent Company Information
11.2.2 Catalent Pharmaceutical CDMO Product Offered
11.2.3 Catalent Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Catalent Main Business Overview
11.2.5 Catalent Latest Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Information
11.3.2 Thermo Fisher Scientific Pharmaceutical CDMO Product Offered
11.3.3 Thermo Fisher Scientific Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Thermo Fisher Scientific Main Business Overview
11.3.5 Thermo Fisher Scientific Latest Developments
11.4 Samsung Biologics
11.4.1 Samsung Biologics Company Information
11.4.2 Samsung Biologics Pharmaceutical CDMO Product Offered
11.4.3 Samsung Biologics Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Samsung Biologics Main Business Overview
11.4.5 Samsung Biologics Latest Developments
11.5 Fareva
11.5.1 Fareva Company Information
11.5.2 Fareva Pharmaceutical CDMO Product Offered
11.5.3 Fareva Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Fareva Main Business Overview
11.5.5 Fareva Latest Developments
11.6 WuXi AppTech
11.6.1 WuXi AppTech Company Information
11.6.2 WuXi AppTech Pharmaceutical CDMO Product Offered
11.6.3 WuXi AppTech Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 WuXi AppTech Main Business Overview
11.6.5 WuXi AppTech Latest Developments
11.7 WuXi Biologics
11.7.1 WuXi Biologics Company Information
11.7.2 WuXi Biologics Pharmaceutical CDMO Product Offered
11.7.3 WuXi Biologics Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 WuXi Biologics Main Business Overview
11.7.5 WuXi Biologics Latest Developments
11.8 Siegfried
11.8.1 Siegfried Company Information
11.8.2 Siegfried Pharmaceutical CDMO Product Offered
11.8.3 Siegfried Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Siegfried Main Business Overview
11.8.5 Siegfried Latest Developments
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Company Information
11.9.2 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Product Offered
11.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 FUJIFILM Diosynth Biotechnologies Main Business Overview
11.9.5 FUJIFILM Diosynth Biotechnologies Latest Developments
11.10 Asymchem
11.10.1 Asymchem Company Information
11.10.2 Asymchem Pharmaceutical CDMO Product Offered
11.10.3 Asymchem Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Asymchem Main Business Overview
11.10.5 Asymchem Latest Developments
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Company Information
11.11.2 Pfizer CentreOne Pharmaceutical CDMO Product Offered
11.11.3 Pfizer CentreOne Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Pfizer CentreOne Main Business Overview
11.11.5 Pfizer CentreOne Latest Developments
11.12 Delpharm
11.12.1 Delpharm Company Information
11.12.2 Delpharm Pharmaceutical CDMO Product Offered
11.12.3 Delpharm Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Delpharm Main Business Overview
11.12.5 Delpharm Latest Developments
11.13 Recipharm
11.13.1 Recipharm Company Information
11.13.2 Recipharm Pharmaceutical CDMO Product Offered
11.13.3 Recipharm Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Recipharm Main Business Overview
11.13.5 Recipharm Latest Developments
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Company Information
11.14.2 AGC Pharma Chemicals Pharmaceutical CDMO Product Offered
11.14.3 AGC Pharma Chemicals Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 AGC Pharma Chemicals Main Business Overview
11.14.5 AGC Pharma Chemicals Latest Developments
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Company Information
11.15.2 Boehringer Ingelheim Pharmaceutical CDMO Product Offered
11.15.3 Boehringer Ingelheim Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Boehringer Ingelheim Main Business Overview
11.15.5 Boehringer Ingelheim Latest Developments
11.16 Vetter
11.16.1 Vetter Company Information
11.16.2 Vetter Pharmaceutical CDMO Product Offered
11.16.3 Vetter Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 Vetter Main Business Overview
11.16.5 Vetter Latest Developments
11.17 Curia
11.17.1 Curia Company Information
11.17.2 Curia Pharmaceutical CDMO Product Offered
11.17.3 Curia Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 Curia Main Business Overview
11.17.5 Curia Latest Developments
11.18 Aenova
11.18.1 Aenova Company Information
11.18.2 Aenova Pharmaceutical CDMO Product Offered
11.18.3 Aenova Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 Aenova Main Business Overview
11.18.5 Aenova Latest Developments
11.19 Porton
11.19.1 Porton Company Information
11.19.2 Porton Pharmaceutical CDMO Product Offered
11.19.3 Porton Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.19.4 Porton Main Business Overview
11.19.5 Porton Latest Developments
11.20 Piramal
11.20.1 Piramal Company Information
11.20.2 Piramal Pharmaceutical CDMO Product Offered
11.20.3 Piramal Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.20.4 Piramal Main Business Overview
11.20.5 Piramal Latest Developments
11.21 Strides Pharma
11.21.1 Strides Pharma Company Information
11.21.2 Strides Pharma Pharmaceutical CDMO Product Offered
11.21.3 Strides Pharma Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.21.4 Strides Pharma Main Business Overview
11.21.5 Strides Pharma Latest Developments
11.22 NextPharma
11.22.1 NextPharma Company Information
11.22.2 NextPharma Pharmaceutical CDMO Product Offered
11.22.3 NextPharma Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.22.4 NextPharma Main Business Overview
11.22.5 NextPharma Latest Developments
11.23 Famar
11.23.1 Famar Company Information
11.23.2 Famar Pharmaceutical CDMO Product Offered
11.23.3 Famar Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.23.4 Famar Main Business Overview
11.23.5 Famar Latest Developments
11.24 Jubilant
11.24.1 Jubilant Company Information
11.24.2 Jubilant Pharmaceutical CDMO Product Offered
11.24.3 Jubilant Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.24.4 Jubilant Main Business Overview
11.24.5 Jubilant Latest Developments
11.25 Alcami
11.25.1 Alcami Company Information
11.25.2 Alcami Pharmaceutical CDMO Product Offered
11.25.3 Alcami Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.25.4 Alcami Main Business Overview
11.25.5 Alcami Latest Developments
11.26 Euroapi
11.26.1 Euroapi Company Information
11.26.2 Euroapi Pharmaceutical CDMO Product Offered
11.26.3 Euroapi Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.26.4 Euroapi Main Business Overview
11.26.5 Euroapi Latest Developments
11.27 Eurofins
11.27.1 Eurofins Company Information
11.27.2 Eurofins Pharmaceutical CDMO Product Offered
11.27.3 Eurofins Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.27.4 Eurofins Main Business Overview
11.27.5 Eurofins Latest Developments
11.28 Avid Bioservices
11.28.1 Avid Bioservices Company Information
11.28.2 Avid Bioservices Pharmaceutical CDMO Product Offered
11.28.3 Avid Bioservices Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.28.4 Avid Bioservices Main Business Overview
11.28.5 Avid Bioservices Latest Developments
11.29 BioVectra
11.29.1 BioVectra Company Information
11.29.2 BioVectra Pharmaceutical CDMO Product Offered
11.29.3 BioVectra Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.29.4 BioVectra Main Business Overview
11.29.5 BioVectra Latest Developments
11.30 CPL
11.30.1 CPL Company Information
11.30.2 CPL Pharmaceutical CDMO Product Offered
11.30.3 CPL Pharmaceutical CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.30.4 CPL Main Business Overview
11.30.5 CPL Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
